AnaptysBio Drops AD Drug After Phase 2 Trial Misses Its Marks
AnaptysBio, Inc. is pulling the plug on ANB032, an investigational B and T lymphocyte attenuator (BTLA)agonist that did not meet the primary and secondary endpoints in an atopic dermatitis (AD) study. The drug was being studied as a monotherapy for moderate-to-severe AD in the global, 201-patient ARISE-AD trial. Despite disappointing efficacy, ANB032 was well tolerated with […]